trending Market Intelligence /marketintelligence/en/news-insights/trending/i8oNM_KiM9bb1NICoWSGfQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Delaware court dismisses C.R. Bard's patent case against AngioDynamics

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Delaware court dismisses C.R. Bard's patent case against AngioDynamics

AngioDynamics Inc. said the U.S. District Court for the District of Delaware dismissed C.R. Bard Inc.'s patent infringement case against the company.

The lawsuit, filed March 2015, claimed certain implantable port products made by AngioDynamics infringed on C.R. Bard's three patents. C.R. Bard, which was acquired by Becton Dickinson and Co. in a $24 billion deal, was seeking unspecified damages and other relief in the case.

AngioDynamics will maintain its focus on delivering products to its customers, the company's President and CEO Jim Clemmer said in a March 8 news release about the matter.

In May 2017, AngioDynamics filed a lawsuit against C.R. Bard for allegedly violating federal antitrust laws by tying the sales of its tip location devices with its own peripherally inserted central catheters.

Latham, N.Y.-based AngioDynamics provides minimally invasive medical devices for use in vascular access, peripheral vascular disease and oncology.